Healthcare Dec 20, 2020 02:22 PM (GMT+8) · EqualOcean
On December 20, first finance reporter learned from Fosun Pharmaceutical that as of December 19, 960 subjects had been enrolled in the domestic phase II clinical trial of bnt162b2, a new RNA crown nucleic acid vaccine. At present, no serious adverse event was reported.